

## Supplements to Torsade de Pointes/QT Prolongation Associated with Antifungal Triazoles: A Pharmacovigilance Study Based on the U.S. FDA Adverse Event Reporting System (FAERS)

Zicheng Yu, Xiaolan Liao. J Pharm Pharm Sci (www.cspsCanada.org) 25, 237 - 243, 2022

**Table SUPPL 1.** Two-by-two contingency table for analysis.

| Drugs                | Thyroid dysfunction cases | All other adverse event cases | Total   |
|----------------------|---------------------------|-------------------------------|---------|
| Antifungal triazoles | a                         | b                             | a+b     |
| All other drugs      | c                         | d                             | c+d     |
| Total                | a+c                       | b+d                           | a+b+c+d |

**Table SUPPL 2.** Summary of major algorithms used for signal detection.

| Algorithms | Equation  | Criteria                     |
|------------|---|------------------------------|
| ROR        | ROR=ad/c/b<br>95% CI=e <sup>ln(ROR)±1.96(1/a+1/b+1/c+1/d)<sup>0.5</sup></sup>                                   | lower limit of 95% CI>1, N≥2 |
| PRR        | PRR=a(c+d)/c/(a+b)<br>$\chi^2=[(ad-bc)^2]/[(a+b)(c+d)(a+c)(b+d)]$   | PRR≥2, $\chi^2$ ≥4, N≥3      |
| BCPNN      | IC=log <sub>2</sub> [a(a+b+c+d)]/[(a+c)(a+b)]<br>95% CI=e <sup>ln(IC)±1.96(1/a+1/b+1/c+1/d)<sup>0.5</sup></sup> | IC025>0                      |
| MGPS       | EBGM=a(a+b+c+d)/(a+c)/(a+b)<br>95% CI=e <sup>ln(EBGM)±1.96(1/a+1/b+1/c+1/d)<sup>0.5</sup></sup>                 | EBGM05>2, N>0                |

N, number of adverse event reports; ROR, reporting odds ratio; CI, confidence interval; N, the number of co-occurrences; PRR, proportional reporting ratio;  $\chi^2$ , chi-squared; BCPNN, Bayesian confidence propagation neural network; IC, information component; IC025, the lower limit of the 95% two-sided CI of the IC; MGPS, multi-item gamma Poisson shrinker; EBGM, empirical Bayesian geometric mean; EBGM05, the lower 95% one-sided CI of EBGM.